learndrugs
Oncology

Cancer Fundamentals & Treatment Care

Oncology basics High-yield Verified · Sep 2026

Cancer is a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body. It is a genetic disease — caused by changes to the genes that control how cells grow and divide — but those changes are usually acquired rather than inherited.

The page behind the naming rule that surprises families, the stage that never changes, the four screening ages that actually moved, and the reason marrow, gut lining and hair follicles suffer together.

What’s going wrong in the body

The normal physiology, where it fails, and why the body’s compensation backfires.

01 What cancer is — and the three things it is not

Start with what normal tissue does, because cancer is that process breaking. In the National Cancer Institute’s words: "Normally, human cells grow and multiply (through a process called cell division) to form new cells as the body needs them. When cells grow old or become damaged, THEY DIE, AND NEW CELLS TAKE THEIR PLACE. Sometimes this orderly process breaks down, and abnormal or damaged cells GROW AND MULTIPLY WHEN THEY SHOULDN’T. These cells may form TUMORS, which are lumps of tissue." And immediately the first correction: "Tumors can be cancerous or not cancerous (BENIGN)." The definition of the disease itself is one sentence — "cancer is a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body" — and cancer "can start almost anywhere in the human body, which is made up of trillions of cells."

Benign versus malignant is a statement about behaviour, not about danger. Malignant: "CANCEROUS TUMORS SPREAD INTO, OR INVADE, NEARBY TISSUES AND CAN TRAVEL TO DISTANT PLACES IN THE BODY TO FORM NEW TUMORS (a process called METASTASIS)." Benign: "BENIGN TUMORS DO NOT SPREAD INTO, OR INVADE, NEARBY TISSUES. WHEN REMOVED, BENIGN TUMORS USUALLY DON’T GROW BACK, WHEREAS CANCEROUS TUMORS SOMETIMES DO." Then the caveat that stops "benign" from meaning "harmless": "BENIGN TUMORS CAN SOMETIMES BE QUITE LARGE, HOWEVER. SOME CAN CAUSE SERIOUS SYMPTOMS OR BE LIFE THREATENING, SUCH AS BENIGN TUMORS IN THE BRAIN." A benign meningioma in a closed skull kills by mass effect while never invading anything.

And two more things are not cancer — yet. "Not every change in the body’s tissues is cancer. Some tissue changes may develop into cancer if they are not treated, however." HYPERPLASIA "occurs when cells within a tissue MULTIPLY FASTER THAN NORMAL and extra cells build up. HOWEVER, THE CELLS AND THE WAY THE TISSUE IS ORGANIZED STILL LOOK NORMAL under a microscope," and it "can be caused by several factors or conditions, including CHRONIC IRRITATION." CARCINOMA IN SITU sits one step further along and carries a deliberately contradictory label: it is numbered as Stage 0 — "abnormal cells are present but have NOT SPREAD to nearby tissue" — and in the same sentence NCI writes "CIS IS NOT CANCER, BUT IT MAY BECOME CANCER." That tension is exactly why screen-detected in-situ disease is argued about. Finally, the shape rule: "Many cancers form solid tumors, but CANCERS OF THE BLOOD, SUCH AS LEUKEMIAS, GENERALLY DO NOT."

The vocabulary, in the order it goes wrong. A tumour is not automatically cancer, benign is not automatically harmless, and two named tissue changes — hyperplasia and carcinoma in situ — sit before cancer rather than inside it.

02 A genetic disease that is usually not inherited

The sentence students most often mishear: "Cancer is a GENETIC DISEASE — that is, it is caused by CHANGES TO GENES that control the way our cells function, especially how they grow and divide." Genetic does not mean inherited. Those changes arise three ways: "of ERRORS THAT OCCUR AS CELLS DIVIDE · of DAMAGE TO DNA CAUSED BY HARMFUL SUBSTANCES IN THE ENVIRONMENT, such as the chemicals in TOBACCO SMOKE and ULTRAVIOLET RAYS from the sun · they were INHERITED FROM OUR PARENTS." Only the third route runs in families, and it is the smallest of the three. The ageing link follows from the same page: "The body NORMALLY ELIMINATES CELLS WITH DAMAGED DNA BEFORE THEY TURN CANCEROUS. But the body’s ability to do so GOES DOWN AS WE AGE," and "most often, cancer-causing genetic changes ACCUMULATE SLOWLY as a person ages."

Three gene classes carry almost all of it, and NCI names them drivers. "The genetic changes that contribute to cancer tend to affect THREE MAIN TYPES OF GENES — PROTO-ONCOGENES, TUMOR SUPPRESSOR GENES, AND DNA REPAIR GENES. These changes are sometimes called ‘DRIVERS’ of cancer." Proto-oncogenes are "involved in NORMAL cell growth and division. However, when these genes are ALTERED in certain ways or are MORE ACTIVE THAN NORMAL, they may become cancer-causing genes (or ONCOGENES), allowing cells to GROW AND SURVIVE WHEN THEY SHOULD NOT" — an oncogene "CANNOT BE TURNED OFF, so they cause UNCONTROLLED CELL GROWTH." Tumour suppressors are "also involved in CONTROLLING cell growth and division," and "in normal cells, TUMOR SUPPRESSOR GENES PREVENT CANCER BY SLOWING OR STOPPING CELL GROWTH. DNA changes that INACTIVATE tumor suppressor genes can lead to uncontrolled cell growth." DNA repair genes are "involved in FIXING DAMAGED DNA. Cells with mutations in these genes tend to DEVELOP ADDITIONAL MUTATIONS in other genes." The image that holds: a stuck accelerator, a failed brake, and lost proofreading.

p53 is the one gene worth naming, because it sits at the junction of all three jobs. It is the main tumor-suppressor transcription factor of the cell cycle, promoting growth arrest, DNA repair and eventual apoptosis. It arrests growth, it calls for repair, and when repair fails it orders the cell to die — the three jobs that the three gene classes divide between them. What the changes add up to is a cell that does eight things normal cells do not: grow without signals, ignore stop and apoptosis signals, invade and spread, "TELL BLOOD VESSELS TO GROW TOWARD TUMORS," hide from the immune system, "TRICK THE IMMUNE SYSTEM INTO HELPING" them, accumulate chromosomal duplications and deletions, and "RELY ON DIFFERENT KINDS OF NUTRIENTS" to grow faster. And every tumour is its own experiment: "Each person’s cancer has a UNIQUE COMBINATION of genetic changes… EVEN WITHIN THE SAME TUMOR, DIFFERENT CELLS MAY HAVE DIFFERENT GENETIC CHANGES." That heterogeneity is the sourced reason resistance develops.

Carcinogenesis as the National Cancer Institute describes it. Three origins of a genetic change, three classes of gene it can hit, one set of resulting behaviours — and both the reason resistance appears and the reason targeted therapy works fall out of the same picture.

03 Metastasis — six steps, two routes, and the naming rule

Metastasis has a definition and a stage attached to it: "Cancer that spreads from where it started to a DISTANT part of the body is called METASTATIC CANCER. For many types of cancer, it is also called STAGE 4 cancer." The sequence is six steps, and every one of them is a place the cell can fail: "growing into, or INVADING, nearby normal tissue · MOVING THROUGH THE WALLS of nearby lymph nodes or blood vessels · TRAVELING through the LYMPHATIC SYSTEM AND BLOODSTREAM to other parts of the body · STOPPING IN SMALL BLOOD VESSELS at a distant location, invading the blood vessel walls, and moving into the surrounding tissue · GROWING in this tissue until a tiny tumor forms · CAUSING NEW BLOOD VESSELS TO GROW, which creates a blood supply that allows the metastatic tumor to continue growing." The two routes to name are lymphatic and haematogenous; direct local invasion is step one rather than a third route.

Most of the cells that set out do not arrive, and some arrive and sleep. "MOST OF THE TIME, SPREADING CANCER CELLS DIE at some point in this process. But, as long as conditions are favorable for the cancer cells at every step, some of them are able to form new tumors." And: "Metastatic cancer cells can also REMAIN INACTIVE AT A DISTANT SITE FOR MANY YEARS BEFORE THEY BEGIN TO GROW AGAIN, IF AT ALL." Dormancy is the sourced reason a cancer can recur a decade later and the reason survivorship follow-up exists. Where they land is not random: "Cancer can spread to ALMOST ANY part of the body, although different types of cancer are MORE LIKELY to spread to certain areas than others. THE MOST COMMON SITES WHERE CANCER SPREADS ARE BONE, LIVER, AND LUNG." When the trail runs the other way and no origin can be found, the diagnosis has a name: "CANCER OF UNKNOWN PRIMARY ORIGIN, or CUP."

Now the naming rule, which is the single most examinable fact on this page and the one families most often get wrong. "Metastatic cancer has the SAME NAME and the SAME TYPE OF CANCER CELLS as the original, or primary, cancer. For example, BREAST CANCER THAT FORMS A METASTATIC TUMOR IN THE LUNG IS METASTATIC BREAST CANCER, NOT LUNG CANCER," and it "is TREATED AS STAGE 4 BREAST CANCER, NOT AS LUNG CANCER." The proof is under the microscope: "When observed under a microscope and tested in other ways, metastatic cancer cells have features like that of the PRIMARY cancer and NOT like the cells in the place where the metastatic cancer is FOUND. THIS IS HOW DOCTORS CAN TELL that it is cancer that has spread." And the reason all of this matters more than the primary tumour ever did: "Metastatic tumors can cause SEVERE DAMAGE to how the body functions, and MOST PEOPLE WHO DIE OF CANCER DIE OF METASTATIC DISEASE."

The six steps, the two routes, and the rule that follows from them. Because the cells stay themselves the whole way, a metastasis keeps the primary’s name and the primary’s treatment.

Causes & risk factors

Modifiable factors are teaching targets — the patient can act on them.

Older age — "the body normally eliminates cells with damaged DNA before they turn cancerous. But the body’s ability to do so goes down as we age," and cancer-causing changes "accumulate slowly as a person ages" Tobacco smoke — NCI names "the chemicals in tobacco smoke" among the harmful environmental substances that damage DNA modifiable Ultraviolet radiation — NCI names "ultraviolet rays from the sun" alongside tobacco smoke as an environmental cause of DNA damage modifiable Inherited mutations — one of the three sourced origins of a cancer-causing change, and the only one that runs in families A known BRCA mutation, or a first-degree relative with one — a hereditary finding that changes how intensively a person is screened, not a gene class this page defines Chronic irritation — named among the causes of hyperplasia, one of the tissue changes that are not cancer but are monitored because they could become it. NCI attaches the caveat to the category rather than to one member of it: "some tissue changes MAY develop into cancer if they are not treated," and "hyperplasia and dysplasia MAY OR MAY NOT become cancer" modifiable Previous cancer treatment — "secondary malignancies like treatment-related MDS/AML" are reported from alkylating agents and topoisomerase II inhibitors, presenting "5 TO 7 YEARS AFTER THE DRUG EXPOSURE"

Signs & symptoms

Each finding tied to the mechanism that produces it — and the triage it calls for.

Nothing at all — the presentation screening exists to catch early Expected
Why: Screening is aimed at people with no symptoms, and its purpose is stated in the recommendation itself. The Task Force recommends biennial breast screening from 40 through 74 "to reduce their risk of DYING from this disease," and it headlines the finalised guidance as "Screening Saves Lives from Breast Cancer." The colorectal recommendation likewise applies to "adults 45 years and older who do NOT have signs or symptoms" and who are at average risk. So asking about symptoms is not screening, and a patient who feels well is exactly the patient the programme is for.
A lump — or no lump at all Hold & notify
Why: Tumours are "lumps of tissue," but the rule has a large exception: "Many cancers form solid tumors, but CANCERS OF THE BLOOD, SUCH AS LEUKEMIAS, GENERALLY DO NOT." A patient with a haematologic malignancy has no mass to find, which is why the leukemias page is built on counts rather than on imaging.
A large, symptomatic or life-threatening mass that is entirely benign Hold & notify
Why: "Benign tumors can sometimes be quite large, however. SOME CAN CAUSE SERIOUS SYMPTOMS OR BE LIFE THREATENING, SUCH AS BENIGN TUMORS IN THE BRAIN." The benign–malignant distinction describes invasion and spread, not danger — a distinction worth making out loud when a family hears "benign" and stops listening.
Severe organ dysfunction from metastases rather than from the primary late Hold & notify
Why: "Metastatic tumors can cause SEVERE DAMAGE to how the body functions, and MOST PEOPLE WHO DIE OF CANCER DIE OF METASTATIC DISEASE." Treatment goals shift with it: "in some cases, treatment may help PROLONG THE LIVES of people with metastatic cancer. In other cases, the primary goal… is to CONTROL THE GROWTH of the cancer or to RELIEVE SYMPTOMS."
Metastatic disease with no identifiable primary Hold & notify
Why: "Sometimes when people are diagnosed with metastatic cancer, doctors CANNOT TELL WHERE IT STARTED. This type of cancer is called CANCER OF UNKNOWN PRIMARY ORIGIN, or CUP." It is a real diagnosis, not an incomplete workup.
Recurrence years after apparently successful treatment late Hold & notify
Why: Sourced directly to dormancy: "Metastatic cancer cells can also REMAIN INACTIVE AT A DISTANT SITE FOR MANY YEARS BEFORE THEY BEGIN TO GROW AGAIN, IF AT ALL." This is why "cured" is a word oncology uses carefully and why follow-up schedules run for years.
Myelosuppression, nausea and vomiting, mucositis, alopecia — the treatment picture, all at once Hold & notify
Why: One sentence explains the entire symptom set: "MOST CHEMOTHERAPY DRUGS SHOW ACTIVITY IN RAPIDLY MULTIPLYING CELLS, SO THEY TEND TO AFFECT RAPIDLY MULTIPLYING CELLS, eg, BONE MARROW, GI TRACT, AND HAIR FOLLICLES. Common toxicities associated with such agents include MYELOSUPPRESSION, NAUSEA, VOMITING, GI SIDE EFFECTS, MUCOSITIS, ALOPECIA, STERILITY, INFERTILITY, AND INFUSION REACTIONS." Three fast-turnover tissues, three symptom clusters.
Mouth soreness and ulceration in the first two weeks of treatment early Hold & notify
Why: Oral mucositis — "a severely debilitating condition characterized by ERYTHEMA, EDEMA, AND ULCERATIONS OF THE ORAL MUCOSA," complicating radiation to the head and neck, chemotherapy, chemoradiotherapy and stem-cell transplantation. "Between 20% to 40% of patients with solid tumors receiving chemotherapy develop mucositis, USUALLY WITHIN FIVE TO FOURTEEN DAYS OF STARTING TREATMENT." The basal epithelial layer has "a RAPID CELLULAR TURNOVER," which puts it on the same list as marrow and hair.
Fever while on chemotherapy Report immediately
Why: An emergency. Two sourced windows coincide: the neutrophil nadir after a cycle, and the loss of the mucosal barrier from mucositis, whose "lesions weaken the mucosa barrier resulting in LOCAL OR SYSTEMIC INFECTION." Febrile neutropenia has a two-part definition — a single oral temperature ≥38.3 °C or ≥38.0 °C sustained an hour, together with an ANC below 500/mm³ or expected to fall below 500 within 48 hours (as carried on the leukemias page) — and below 500/µL is also where the severity ladder puts SEVERE neutropenia. The management pathway is owned by the leukemias and oncologic-emergencies pages.
Anxiety, depression and anticipatory grief Hold & notify
Why: Named as clinical problems, not as background noise: "Patients undergoing chemotherapy usually need STRONG EMOTIONAL SUPPORT, and they are going through ANXIETY, DEPRESSION, AND ANTICIPATORY GRIEF from the expected side effects of the drugs. MULTIDISCIPLINARY AND INTERPROFESSIONAL INTERVENTIONS at various stages of their treatment regimen can PROMOTE MENTAL HEALTH."
A new leukaemia or myelodysplastic syndrome five to seven years after treatment late Hold & notify
Why: "Secondary malignancies like treatment-related MDS/AML(t-MDS/t-AML) are RARE complications with POOR PROGNOSIS and have often been reported from ALKYLATING AGENTS AND TOPOISOMERASE II INHIBITORS… These patients usually present 5 TO 7 YEARS AFTER THE DRUG EXPOSURE." It is the reason a survivorship history has to include which agents were given, not just which cancer was treated.

Diagnostics

Test In this disorder Normal
Staging — what it is and what it decides Knowing the stage "helps your doctor UNDERSTAND HOW SERIOUS your cancer is and your CHANCES OF SURVIVAL, PLAN THE BEST TREATMENT for you, and IDENTIFY CLINICAL TRIALS that may be treatment options." Note that there is no single system: "there are MANY staging systems. Some, such as the TNM staging system, are used for many types of cancer. Others are specific to a particular type of cancer" — and "examples of cancers with DIFFERENT staging systems include BRAIN AND SPINAL CORD TUMORS AND BLOOD CANCERS." "Stage refers to the EXTENT of your cancer, such as HOW LARGE the tumor is and IF IT HAS SPREAD." Every staging system includes "where the TUMOR IS LOCATED · the SIZE of the tumor · whether the cancer has spread to NEARBY LYMPH NODES · whether the cancer has spread to a DIFFERENT PART OF THE BODY" —
The TNM system It is "the MOST WIDELY USED cancer staging system. Most hospitals and medical centers use the TNM system as their main method for cancer reporting." Letters may subdivide for detail — "such as T3a and T3b." Read a TNM string as three separate questions: how big, how many nodes, has it left. "The T refers to the SIZE AND EXTENT OF THE MAIN TUMOR… The N refers to the NUMBER OF NEARBY LYMPH NODES THAT HAVE CANCER. The M refers to WHETHER THE CANCER HAS METASTASIZED." T: TX: cannot be measured · T0: cannot be found · T1 to T4: size and extent, the higher the number, the larger the tumor or the more it has grown into nearby tissues. N: NX: cannot be measured · N0: no cancer in nearby nodes · N1 to N3: the higher the number, the more lymph nodes contain cancer. M: MX: cannot be measured · M0: has not spread · M1: has spread. Worked examples: T1N0MX or T3N1M0 —
Stage groupings and the registry categories The registry categories are "more often used by cancer registries than by doctors" — but they are the vocabulary behind every published survival statistic a patient will find online, so knowing which language a number is written in matters. Stage 0: "Abnormal cells are present but have not spread to nearby tissue. Also called carcinoma in situ, or CIS." Stage I, Stage II, and Stage III: "Cancer is present. The higher the number, the larger the cancer tumor and the more it has spread into nearby tissues." Stage IV: "The cancer has spread to distant parts of the body." Sub-lettering follows the same idea — "stage 2 prostate cancer may be further divided into 2A, 2B, or 2C." The five-category registry system runs in situ · localized · regional · distant · unknown —
The stage at diagnosis is the stage forever This one reliably surprises students and patients alike. A stage II cancer that later metastasises is documented as stage II with metastatic disease, not restaged as IV. Explaining it in advance prevents a family reading a chart and concluding that someone made an error. "A cancer is ALWAYS REFERRED TO BY THE STAGE IT WAS GIVEN AT DIAGNOSIS, EVEN IF IT GETS WORSE OR SPREADS. New information about how a cancer has changed over time is ADDED TO the original stage. SO THE STAGE DOESN’T CHANGE, EVEN THOUGH THE CANCER MIGHT" —
Pathology of a metastatic lesion "THIS IS HOW DOCTORS CAN TELL that it is cancer that has spread" rather than a second, new primary — and it is the evidence behind the naming rule. The practical consequence is that the biopsy result, not the location of the lesion, decides what the disease is called and how it is treated. "Metastatic cancer cells GENERALLY LOOK THE SAME as cells of the original cancer… metastatic cancer cells and cells of the original cancer usually have some MOLECULAR FEATURES IN COMMON, such as the presence of SPECIFIC CHROMOSOME CHANGES" —
Colorectal cancer screening — USPSTF, 18 May 2021 The change worth knowing: "the USPSTF EXPANDED the recommended ages for colorectal cancer screening to 45 to 75 years (PREVIOUSLY, IT WAS 50 TO 75 YEARS)." It applies to average-risk adults without symptoms — no prior colorectal cancer or adenomatous polyps, no inflammatory bowel disease, and no personal or family history of predisposing genetic disorders. Adults 50 to 75 — screen. GRADE A. Adults 45 to 49 — screen. GRADE B. Adults 76 to 85 — "SELECTIVELY OFFER" screening, because "the NET BENEFIT of screening ALL persons in this age group is SMALL." GRADE C. Strategies include "HSgFOBT or FIT EVERY YEAR · stool DNA-FIT EVERY 1 TO 3 YEARS," with colonoscopy every 10 years, flexible sigmoidoscopy every 5 years and CT colonography every 5 years —
Breast cancer screening — USPSTF, 30 April 2024 This edition replaced the individualised-decision approach, in the Task Force’s own words: "PREVIOUSLY, WE RECOMMENDED THAT WOMEN IN THEIR 40s MAKE AN INDIVIDUAL DECISION WITH THEIR CLINICIAN… The Task Force NOW recommends that all women start getting screened… EVERY OTHER YEAR STARTING AT AGE 40." Nearly half of all women have DENSE BREASTS, "which INCREASES THEIR RISK for breast cancer and means that MAMMOGRAMS MAY NOT WORK AS WELL for them" — they should still start at 40 and discuss follow-up testing. Older textbooks and even recently updated review chapters still print "50 to 74 biennial, 40 to 49 individualized." That is the superseded recommendation. "The Task Force recommends that ALL WOMEN GET SCREENED FOR BREAST CANCER EVERY OTHER YEAR, STARTING AT AGE 40 AND CONTINUING THROUGH AGE 74, to reduce their risk of dying from this disease. THIS IS A B GRADE" —
Cervical and lung cancer screening — read the statements themselves Why a page that gives colorectal and breast in full stops short here: those two statements are cited below and these two are not, and a number without a listed source is a number you cannot check. The risk is concrete rather than theoretical — widely used review chapters still print superseded USPSTF figures for lung and breast screening, so a reader who meets a different number has no way to tell which edition it came from. One thing is worth carrying anyway, because it is not a figure: the cervical recommendation is under revision by the Task Force, so anything quoted for it needs its date checked before it is used. The USPSTF also issues cervical and lung cancer screening recommendations, and this page does not print their figures. The ages, intervals, grades and smoking-history bands for both must be read from the current USPSTF final recommendation statements, which are the only place they can be relied on —

Complications

Warning: Metastatic disease Hold & notify
"Metastatic tumors can cause SEVERE DAMAGE to how the body functions, and MOST PEOPLE WHO DIE OF CANCER DIE OF METASTATIC DISEASE."
The heralding cues are organ-specific and follow the commonest destinations — bone, liver and lung. What changes at this point is the goal of treatment rather than the intensity of care: "in some cases, treatment may help prolong the lives of people with metastatic cancer. In other cases, the primary goal… is to control the growth of the cancer or to relieve symptoms." Dormancy means this can appear years after treatment ended, because cells "remain inactive at a distant site for many years before they begin to grow again."
Warning: Infection through two simultaneous breaches Report immediately
Myelosuppression is the dose-limiting toxicity of most chemotherapy, and mucositis "lesions weaken the mucosa barrier resulting in LOCAL OR SYSTEMIC INFECTION." The nadir and the mucositis window overlap, which is why fever in a patient on chemotherapy is an emergency.
The sourced nadir figure belongs to one agent class, not to chemotherapy as a whole: "neutropenia nadir: 6 to 10 days with recovery in 14 to 21 days." Teach the concept — the count falls to a low point after a cycle, infection risk peaks there, then it recovers — and get the actual numbers from the regimen in front of you. Purine analogues add a second mechanism: they "suppress CD4+ cells," putting patients at risk of opportunistic infections. An ANC below 500/µL is SEVERE neutropenia; the febrile-neutropenia definition, risk stratification and the one-hour antibiotic rule live on the leukemias and oncologic-emergencies pages.
Warning: The five oncologic emergencies Report immediately
Tumour lysis syndrome, superior vena cava syndrome, spinal cord compression, hypercalcaemia of malignancy and febrile neutropenia — named here so they are recognised, developed on the oncologic-emergencies page.
The nursing point this page owns is the trigger for looking: a patient with a known cancer who develops new back pain, a new facial or arm swelling, a falling urine output after a first chemotherapy cycle, new confusion, or a fever, is a patient who needs the emergency pathway rather than a routine review. Each of those five has its own criteria and its own time limit, and none of them is taught here.
Warning: Cumulative cardiotoxicity Hold & notify
Anthracycline cardiotoxicity is explicitly cumulative, and the source gives a ceiling: "the LIFETIME CUMULATIVE DOSE of adriamycin is 550 mg/m."
Cumulative means the total across the whole treatment history, not per cycle and not per admission — which is why the record of how much a patient has already received travels with them and why a survivor returning years later for a different cancer needs that history reconstructed before an anthracycline is considered again.
Caution: Treatment that causes cancer
"Secondary malignancies like treatment-related MDS/AML(t-MDS/t-AML) are RARE complications with POOR PROGNOSIS and have often been reported from ALKYLATING AGENTS AND TOPOISOMERASE II INHIBITORS… These patients usually present 5 TO 7 YEARS AFTER THE DRUG EXPOSURE."
Named alongside them are "pulmonary fibrosis, infertility" and sterility as long-term and delayed toxicities. The teaching consequence is fertility counselling before treatment starts, not after, and a survivorship record that names the agents.
Caution: Mucositis interrupting the treatment itself Hold & notify
"ORAL INTAKE MAY BE IMPAIRED DUE TO PAIN, which in some cases may lead to the need for PARENTERAL NUTRITION," and in severe chemotherapy-induced mucositis "THE DOSE IN THE SUBSEQUENT CHEMOTHERAPY CYCLE MAY HAVE TO BE DECREASED OR DELAYED, affecting patients’ quality of life and WORSENING PROGNOSIS."
This is what turns oral care from a comfort measure into a treatment-protecting intervention. Risk is highest with agents affecting DNA synthesis in S phase — "5-FLUOROURACIL, METHOTREXATE, AND CYTARABINE" — and rises further with high-dose chemotherapy or bone marrow transplantation (76% risk) and with altered-fractionation head and neck radiotherapy (100%). Two modifiable contributors are named: "the frequency of mucositis is HIGHER in patients with POOR NUTRITIONAL STATUS AND INADEQUATE ORAL CARE."
Caution: Overdiagnosis and overtreatment — complications of screening, not of cancer
The Task Force names them among the harms of screening itself: "potential harms of screening mammography include FALSE-POSITIVE RESULTS, which may lead to psychological harms, additional testing, and invasive follow-up procedures; OVERDIAGNOSIS AND OVERTREATMENT OF LESIONS THAT WOULD NOT HAVE LED TO HEALTH PROBLEMS IN THE ABSENCE OF DETECTION BY SCREENING; and RADIATION EXPOSURE."
The definition inside that sentence is the part to keep — overdiagnosis is finding disease that would never have harmed the person, which is not the same as a false positive and cannot be undone by being more careful. The Task Force adds that "the MOST COMMON harm is a FALSE-POSITIVE result," and that for ductal carcinoma in situ "it is unknown what proportion of screen-detected DCIS represents overdiagnosis." This is why the recommendations are graded rather than simply issued, and why the colorectal one shifts to "selectively offer" at 76 to 85.

Medications for this condition

Why each class is prescribed here — every card links to its full pharmacology page.

Antineoplastic / Chemotherapy Overview First-line High-alert
Oncology

The disorder-side logic in one sentence: chemotherapy targets rapidly dividing cells, which is both why it works and why it hurts. "MOST CHEMOTHERAPY DRUGS SHOW ACTIVITY IN RAPIDLY MULTIPLYING CELLS, SO THEY TEND TO AFFECT RAPIDLY MULTIPLYING CELLS, eg, BONE MARROW, GI TRACT, AND HAIR FOLLICLES. Common toxicities… include MYELOSUPPRESSION, NAUSEA, VOMITING, GI SIDE EFFECTS, MUCOSITIS, ALOPECIA, STERILITY, INFERTILITY, AND INFUSION REACTIONS." Why regimens combine agents: "Multitargeted or COMBINATION therapy is SUPERIOR to single-agent therapy in most cancer treatments," and combinations "with DIFFERENT MECHANISMS OF ACTION and NONOVERLAPPING TOXICITIES can be chosen to DECREASE THE RESISTANCE AND TOXICITIES," appearing to "PREVENT THE DEVELOPMENT OF RESISTANT CLONES by promoting cytotoxicity in RESTING AND DIVIDING cells" — the worked curative example being "bleomycin/vinblastine/cisplatin for testicular cancers." Dosing and interactions belong on the assessment list: agents "are generally administered using BODY SURFACE AREA dosing," and "DRUG-DRUG INTERACTIONS ARE EXPECTED" because cytochrome P450 metabolises many of them — bortezomib, docetaxel, etoposide, imatinib, sunitinib, sorafenib and the vinca alkaloids through CYP3A4/5 — so know the "common drugs with strong INDUCERS like PHENOBARBITAL AND PHENYTOIN and INHIBITORS of CYP enzymes like GRAPEFRUIT JUICE." The nadir is a concept first and a number second: the only sourced figure is one agent class’s "neutropenia nadir: 6 to 10 days with recovery in 14 to 21 days" — there is no universal 7-to-14-day rule, and the clinical instruction does not need one, because fever during the nadir is an emergency regardless of the number. Named toxicity signatures worth carrying: high-dose cytarabine — "neurotoxicity and conjunctivitis"; gemcitabine — liver enzyme elevations and interstitial pneumonitis; methotrexate-type agents — myelosuppression, mucositis, hepatotoxicity, nephrotoxicity, cutaneous reactions; 5-fluorouracil — "dose-limiting HAND-FOOT, mucositis, diarrhea," with toxicity in dihydropyrimidine dehydrogenase deficiency treatable by "uridine triacetate"; taxanes — "hypersensitivity reactions, myelosuppression, peripheral neuropathy"; vinca alkaloids — peripheral neuropathy affecting both motor and sensory function; anthracyclines — cumulative cardiotoxicity. And the psychological load is named as part of the class’s burden, requiring "MULTIDISCIPLINARY AND INTERPROFESSIONAL INTERVENTIONS." The class page owns agent-by-agent pharmacology.
Antiemetics
Digestive / GI · ondansetron

Nausea and vomiting are named class toxicities of chemotherapy, and the mechanism is the same one behind everything else on this page: the agents hit the rapidly multiplying cells of the gastrointestinal tract. The disorder-side reason to treat emesis aggressively is not comfort alone. The same gastrointestinal toxicity produces mucositis, and severe mucositis means "the dose in the subsequent chemotherapy cycle may have to be DECREASED OR DELAYED, affecting patients’ quality of life and WORSENING PROGNOSIS" — while "In severe cases, this can lead to parenteral nutrition." Controlling the gut protects the treatment plan and the nutrition that mucositis risk depends on, since "the frequency of mucositis is higher in patients with poor nutritional status." A patient who cannot keep fluids or food down is also a patient who cannot take oral medicines, which puts the rest of the regimen at risk. The class page owns the agents and their receptor targets.
Opioid Analgesics High-alert
Nervous · morphine

Used here only at the level this page can source: pain control is a core goal of palliative care, available from diagnosis onward rather than at the end. Palliative care is "care meant to IMPROVE THE QUALITY OF LIFE of patients who have a serious or life-threatening disease, such as cancer," and "IT CAN BE GIVEN WITH OR WITHOUT CURATIVE CARE," with the goal "to PREVENT OR TREAT, AS EARLY AS POSSIBLE, the symptoms and side effects of the disease and its treatment." The sourced examples of palliative intervention for pain are procedural rather than pharmacological — "doctors may give CHEMOTHERAPY OR RADIATION THERAPY TO SLOW THE GROWTH OF A TUMOR THAT IS CAUSING PAIN," or "SURGERY may be performed to remove a mass that is pressing on certain nerves and causing pain." Opioid selection, the analgesic ladder and equianalgesic conversion are owned by the class page, not by this one.

Beyond medications

  • RADIATION — the first thing to establish is which kind, because the safety answer depends on it. There are two families. External beam is delivered from outside. Internal radiation puts a source of radiation inside the body, and that source can be solid or liquid. Solid is brachytherapy — "seeds, ribbons, or capsules that contain a radiation source are PLACED IN YOUR BODY, IN OR NEAR THE TUMOR," and like external beam it "is a LOCAL treatment and treats ONLY A SPECIFIC PART of your body," and "It is often used to treat cancers of the head and neck, breast, cervix, prostate, and eye." Liquid is systemic — it travels in the blood to tissues throughout the body — and radioimmunotherapy links a radioactive substance to a monoclonal antibody to carry the radiation to the cancer cells.
  • ❗ THE REASSURANCE THAT IS FULLY SOURCED, and it should be given unprompted: "EXTERNAL BEAM RADIATION THERAPY WILL NOT MAKE YOU RADIOACTIVE. People often wonder if they will be radioactive when they are having treatment with radiation. External beam radiation therapy will not make you radioactive. YOU MAY SAFELY BE AROUND OTHER PEOPLE, EVEN PREGNANT WOMEN, BABIES, AND YOUNG CHILDREN." For brachytherapy the sourced statement is much narrower — only that "the radiation source in your body will give off radiation for a while." For a high-dose implant the source names the precautions: "Staying in a private hospital room to protect others from radiation coming from your body"; staff "may stand at a distance, talk with you from the doorway of your room, and wear protective clothing"; and visitors may need to be "standing by the doorway rather than going into your hospital room," "keeping visits short, about 30 minutes or less each day," and "not having visits from pregnant women and children younger than a year old." Exact dwell times and shielding follow institutional radiation-safety policy.
  • Why radiation has side effects at all, and the skin-marking rule that follows from positioning. Radiation kills or slows cancer cells but also affects nearby healthy cells, and that damage is the side effect — which is why "Radiation is given in a series of treatments to allow healthy cells to recover and to make radiation more effective." The therapist "will TATTOO OR DRAW SMALL DOTS OF COLORED INK ON YOUR SKIN to mark the treatment area. THESE DOTS WILL BE NEEDED THROUGHOUT YOUR COURSE OF RADIATION THERAPY… to make sure you are IN EXACTLY THE SAME POSITION FOR EVERY TREATMENT. The dots are about the size of a FRECKLE." So the instruction is "the markings must stay," and the reason is reproducible positioning — tattooed dots are permanent, drawn ones are not. Patients may also "see COLORED LIGHTS pointed at your skin marks. These lights are HARMLESS."
  • Consent for radiation is an explicit, scheduled conversation. "You will have a 1- to 2-HOUR MEETING with your doctor or nurse before you begin radiation therapy. At this time, you will have a physical exam, talk about your medical history, and maybe have imaging tests. Your doctor or nurse will discuss external beam radiation therapy, its BENEFITS AND SIDE EFFECTS, and WAYS YOU CAN CARE FOR YOURSELF during and after treatment. YOU CAN THEN CHOOSE whether to have external beam radiation therapy." The last sentence is the one to protect.
  • SURGERY on this page is limited to what is sourced: the benign–malignant recurrence principle and the palliative examples. Benign tumours, "when removed… usually don’t grow back, whereas cancerous tumors sometimes do," and surgery appears as a palliative tool — "surgery may be performed to REMOVE A MASS THAT IS PRESSING ON CERTAIN NERVES AND CAUSING PAIN." Curative surgical oncology — margins, sentinel node biopsy, debulking — belongs to the disease-specific pages.
  • PALLIATIVE CARE is a parallel service, not a final one. It "addresses the PERSON AS A WHOLE, NOT JUST THEIR DISEASE," aiming "to PREVENT OR TREAT, AS EARLY AS POSSIBLE, the symptoms and side effects of the disease and its treatment, in addition to any related PSYCHOLOGICAL, SOCIAL, AND SPIRITUAL problems." It is delivered by "a MULTIDISCIPLINARY TEAM that may include doctors, NURSES, registered dieticians, pharmacists, occupational therapists, physical therapists, chaplains, psychologists, and social workers," and that team "WORKS TOGETHER WITH THE ONCOLOGY CARE TEAM." And the same treatments do both jobs — chemotherapy or radiation "to slow the growth of a tumor that is causing pain" is palliative use of a curative tool.
  • ❗ HOSPICE — the distinction in one sourced sentence: "WHEREAS PALLIATIVE CARE CAN BEGIN AT ANY POINT DURING CANCER TREATMENT, HOSPICE CARE BEGINS WHEN CURATIVE TREATMENT IS NO LONGER THE GOAL OF CARE AND THE SOLE FOCUS IS QUALITY OF LIFE." Eligibility, recertification and revocation follow Medicare hospice benefit rules, which change — the hospice team explains them.
  • ❗ HOSPICE BEGINS WHEN THE GOAL CHANGES, not when care stops. It starts when "the sole focus is quality of life," and whether and how a patient can later leave or re-enter hospice is set by Medicare rules that the hospice team explains — say this early, because patients who fear a one-way door delay the conversation.
  • PRIMARY PREVENTION is the half of cancer control that screening does not cover, and the page teaches only the two exposures its sources name. One of the three routes to a cancer-causing genetic change is "DAMAGE TO DNA CAUSED BY HARMFUL SUBSTANCES IN THE ENVIRONMENT, such as the chemicals in TOBACCO SMOKE and ULTRAVIOLET RAYS FROM THE SUN" — and unlike the other two routes, replication error and inheritance, that one is an exposure a person can reduce. The broader lifestyle list belongs on a page that can cite a prevention source; here the principle is enough: screening finds cancer earlier, and reducing a named exposure means there is less to find.

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Assessment & monitoring
Establish which cancer, which stage at diagnosis, and which agents — not just "cancer".
Why: Three sourced reasons. The naming rule means a lung lesion in a patient with breast cancer is metastatic breast cancer, treated as stage 4 breast cancer. The stage does not change — "a cancer is always referred to by the stage it was given at diagnosis, even if it gets worse or spreads," so a chart reading stage II with metastases is correct rather than an error. And the agents matter years later: treatment-related MDS and AML follow alkylating agents and topoisomerase II inhibitors "5 to 7 years after the drug exposure," while anthracycline cardiotoxicity is cumulative across the whole treatment history.
Review the full medication list against CYP interactions before a cycle, including over-the-counter products and foods.
Why: "DRUG-DRUG INTERACTIONS ARE EXPECTED," and "the cytochrome P450 (CYP) enzyme metabolizes various chemotherapeutic drugs," with bortezomib, docetaxel, etoposide, imatinib, sunitinib, sorafenib and vinca alkaloids named through CYP3A4/5. The source specifically calls out strong inducers "like PHENOBARBITAL AND PHENYTOIN" and inhibitors "like GRAPEFRUIT JUICE" — one of which a patient will never think to mention. Dosing is by body surface area, so accurate height and weight are part of the safety check.
Inspect the mouth at every contact from about day five, and ask specifically about pain on eating and drinking.
Why: Mucositis affects "20% to 40% of patients with solid tumors receiving chemotherapy… usually WITHIN FIVE TO FOURTEEN DAYS OF STARTING TREATMENT," rising to 76% with high-dose chemotherapy or bone marrow transplantation and 100% with altered-fractionation head and neck radiotherapy. Finding it early matters because it is both a portal of entry for local or systemic infection and a reason "the dose in the subsequent chemotherapy cycle may have to be decreased or delayed."
Assess nutritional status at baseline and keep assessing it — weight, intake, and whether eating hurts.
Why: The relationship runs both ways and both directions are sourced. Poor nutritional status raises mucositis risk — "the frequency of mucositis is higher in patients with poor nutritional status and inadequate oral care" — and mucositis then impairs intake, since "oral intake may be impaired due to pain, which in some cases may lead to the need for parenteral nutrition." Chemotherapy’s gastrointestinal toxicity compounds both.
Know the infection windows and treat fever in them as an emergency — then hand the patient to the pathway that owns it.
Why: Two windows coincide: the neutrophil nadir after a cycle, when the count is at its lowest and infection risk peaks, and the loss of the mucosal barrier from mucositis. Know the definition well enough to recognise it: a single oral temperature ≥38.3 °C, or ≥38.0 °C sustained over an hour, with an ANC below 500/mm³ or expected to fall below 500 within 48 hours (as carried on the leukemias page) — and remember that below 500/µL is also the severity ladder’s SEVERE band. The MASCC risk stratification and the rule that intravenous antibiotics go in within one hour belong to the leukemias and oncologic-emergencies pages; escalate to that pathway rather than managing it here.
Screening & prevention
Screen the patient in front of you, using the current recommendation and its grade.
Why: Colorectal from 45 (Grade B) through 75 (Grade A), with selective offering from 76 to 85 (Grade C). Breast biennially from 40 through 74 (Grade B) — the 2024 edition. For cervical and lung, read the current USPSTF statements directly — this page prints no figures for either, because neither statement is listed among its sources, and the cervical recommendation is under revision. Grades are not decoration: a Grade C means "selectively offer" because "the net benefit of screening all persons in this age group is small."
Check the edition of whatever source the patient or the unit is quoting before acting on a screening age.
Why: A recent review chapter is not a current guideline. A 2024-updated review still prints the superseded breast figures — "50 to 74 biennial, 40 to 49 individualized" — and superseded lung figures too. The Task Force describes its own change plainly: "previously, we recommended that women in their 40s make an individual decision with their clinician… The Task Force now recommends that all women start getting screened… every other year starting at age 40."
Teach primary prevention in the same conversation as screening.
Why: The two exposures this page can name are the two NCI names: "damage to DNA caused by harmful substances in the environment, such as the chemicals in TOBACCO SMOKE and ULTRAVIOLET RAYS FROM THE SUN." Both are modifiable, and they sit alongside the two routes that are not — replication error and inheritance. Prevention and screening are separate conversations, and doing one is not a reason to skip the other.
Name the inequities the evidence itself names, rather than delivering the recommendation as if it settled everything.
Why: "BLACK WOMEN ARE 40 PERCENT MORE LIKELY TO DIE FROM BREAST CANCER THAN WHITE WOMEN and too often get AGGRESSIVE CANCERS AT YOUNG AGES," and the Task Force states that "ensuring Black women start screening at 40 is an important first step, YET IT IS NOT ENOUGH to improve these inequities." Screening uptake also lags its own targets — Pap testing, mammography and colorectal screening at 80%, 70% and just above 60% against Healthy People 2020 targets of 93%, 81% and 70.5%.
Interventions & safety
Use the oral-care regimen the leukemias page already owns — and do not put the patient on a neutropenic diet.
Why: The sourced regimen is oral rinses four to six times a day with sterile water, normal saline or sodium bicarbonate, and tooth brushing at least twice daily with a soft or ultrasoft toothbrush. Inadequate oral care is a named, modifiable risk factor for mucositis. The neutropenic diet is not supported by the evidence — the leukemias page carries the trial data. Standard food safety replaces it: avoid raw eggs, undercooked meats, unpasteurised products and unwashed raw vegetables.
Protect the radiation skin markings and explain why they exist.
Why: The dots "will be needed THROUGHOUT your course of radiation therapy" so the therapist can "make sure you are in exactly the same position for every treatment." Tattooed dots are permanent; drawn ones are not, and a patient who scrubs them off in the shower has removed the positioning reference. The coloured lights aimed at those marks are explicitly harmless — worth saying, because they look alarming.
Answer the radioactivity question before the patient asks it, and answer it by treatment type.
Why: "External beam radiation therapy will NOT make you radioactive… you may safely be around other people, even pregnant women, babies, and young children." That is a complete, quotable reassurance and it removes a fear that keeps patients away from their families. For internal radiation, the sourced statement is only that "the radiation source in your body will give off radiation for a while" — the actual precautions for a given implant come from the radiation-safety plan for that patient, not from a memorised rule.
Treat nausea and vomiting as plan-protecting, not merely comfort-improving.
Why: Emesis and mucositis share a mechanism — chemotherapy hitting the rapidly multiplying cells of the gastrointestinal tract. Uncontrolled emesis undermines nutrition, which raises mucositis risk, and severe mucositis can force the next cycle to be reduced or delayed, "affecting patients’ quality of life and worsening prognosis." Controlling the gut keeps the regimen on schedule.
Treat anxiety, depression and anticipatory grief as part of the care plan, with a team.
Why: "Patients undergoing chemotherapy usually need strong emotional support, and they are going through anxiety, depression, and anticipatory grief from the expected side effects of the drugs. Multidisciplinary and interprofessional interventions at various stages of their treatment regimen can promote mental health." Palliative care is the structure built for exactly this, and it addresses "psychological, social, and spiritual" problems alongside physical ones.
Patient & family teaching
Teach the naming rule explicitly, using the patient’s own cancer.
Why: "Breast cancer that forms a metastatic tumor in the lung is metastatic BREAST cancer, not lung cancer," and it "is treated as stage 4 breast cancer." Families routinely hear "it has spread to the lung" and conclude a second cancer has appeared — which changes what they expect from treatment and what they search for online. The proof is worth giving too: the cells "have features like that of the primary cancer and not like the cells in the place where the metastatic cancer is found."
Explain that cancer is genetic but usually not inherited, when a patient asks "why me" or "will my children get this".
Why: Use the sourced framing. Cancer "is caused by changes to genes that control the way our cells function," but those changes come from "errors that occur as cells divide," from "damage to DNA caused by harmful substances in the environment, such as the chemicals in tobacco smoke and ultraviolet rays," or from inheritance — and only the third runs in families. Add the ageing explanation: the body "normally eliminates cells with damaged DNA before they turn cancerous. But the body’s ability to do so goes down as we age."
Introduce palliative care early and correct the misunderstanding on the spot.
Why: It "can begin at ANY POINT during cancer treatment" and "can be given WITH OR WITHOUT curative care." A patient receiving palliative chemotherapy or radiation to shrink a painful tumour is not giving up — those are the sourced examples of palliative use of curative tools. Most insurance covers it: "private health insurance usually covers palliative care services," Medicare Part B pays for some symptom-management services, and Medicaid coverage "varies by state."
Explain hospice accurately, including that it can be left and re-entered.
Why: It begins "when curative treatment is no longer the goal of care and the sole focus is quality of life,", and its eligibility, recertification and revocation rules come from Medicare, which the hospice team explains.
Support the choice, not just the plan — before radiation and at every decision point.
Why: The pre-radiation meeting is a scheduled 1- to 2-hour conversation covering "benefits and side effects" and "ways you can care for yourself," and it ends: "YOU CAN THEN CHOOSE whether to have external beam radiation therapy." The palliative team exists in part to hold the same ground, addressing "psychological, social, and spiritual" issues as part of care rather than after it.

How a real nurse thinks

The clinical-judgment loop, worked for a typical presentation — reasoning, not reference.

  1. 1
    Recognize cues

    Four cues are in the chart and three are in her questions. The chart says T2N1M0 — a larger primary with nodal involvement and no distant metastasis, which is what the M0 means and is the single most reassuring element of the string. It says body-surface-area dosing, so height and weight are safety data rather than admission paperwork. It says anthracycline, which puts cumulative lifetime dose on the permanent record. And it says phenytoin and grapefruit juice — a named strong CYP inducer and a named inhibitor, in a patient about to receive agents metabolised through cytochrome P450, where "drug-drug interactions are expected." Her three questions are cues too, because each maps onto a sourced teaching point that is easy to get wrong: the naming rule, the difference between genetic and inherited, and the radioactivity answer that depends on which radiation she is having.

  2. 2
    Analyze cues

    Start with the interaction, because it is the one that can change today’s dose. Phenytoin is named among the strong inducers and grapefruit juice among the inhibitors of the enzymes that metabolise several chemotherapy agents — this belongs to the pharmacist and prescriber before the first infusion, not after it. Then map the toxicity she should expect. "Most chemotherapy drugs show activity in rapidly multiplying cells, so they quickly affect multiplying cells, eg, bone marrow, GI tract, and hair follicles" — which predicts myelosuppression, nausea and vomiting with mucositis, and alopecia, and predicts them as a group rather than as unrelated events. Then the timing. Mucositis appears in "five to fourteen days" from the start of treatment, and the neutrophil count falls to a nadir some days after a cycle — the one sourced figure being 6 to 10 days with recovery at 14 to 21 for a specific agent class, which makes those weeks the window where fever is an emergency. Then the anthracycline, whose cardiotoxicity is explicitly cumulative, with a stated lifetime ceiling. And then her questions, each of which has a quotable answer: a lung lesion would be metastatic breast cancer treated as stage 4 breast cancer; cancer is genetic but the changes usually come from replication errors or environmental damage rather than inheritance; and external beam radiation will not make her radioactive.

  3. 3
    Prioritize

    First, the interaction check — phenytoin and grapefruit juice, escalated to pharmacy and the prescriber before the infusion. Second, accurate height and weight, because the dose is calculated from them. Third, baseline nutritional assessment and the oral-care plan, started now rather than when her mouth is already sore, since poor nutrition and inadequate oral care both raise mucositis risk. Fourth, the infection teaching — what the nadir is, when it falls, and the instruction that fever is an emergency, not a call to wait until morning. Fifth, the cumulative anthracycline record, documented where a future team will find it. Sixth, her three questions, answered properly, because each of them is the kind of misunderstanding that quietly changes behaviour — the naming rule affects what she believes about her prognosis, the inheritance answer affects what she tells her daughters, and the radioactivity answer affects whether she holds her grandchildren. Seventh, introduce palliative care now, alongside curative treatment, before the word acquires the meaning she probably assumes it has.

  4. 4
    Generate solutions

    Anticipate a combination regimen chosen for different mechanisms and non-overlapping toxicities, since combinations "prevent the development of resistant clones by promoting cytotoxicity in resting and dividing cells." Anticipate antiemetic cover as treatment-protecting rather than comfort-only. Anticipate the oral-care regimen the leukemias page owns — rinses four to six times daily with sterile water, saline or sodium bicarbonate, and brushing twice daily with a soft or ultrasoft brush — with no neutropenic diet, which the shipped evidence kills, and standard food safety instead. Anticipate serial counts and a febrile-neutropenia pathway that the oncologic-emergencies and leukemias pages own, remembering that an ANC below 500/µL is severe neutropenia. Anticipate cardiac surveillance and a running cumulative anthracycline total. Anticipate the pre-radiation 1- to 2-hour meeting covering benefits, side effects and self-care, ending in her choice. And anticipate the five oncologic emergencies as things to recognise and escalate — tumour lysis syndrome, superior vena cava syndrome, spinal cord compression, hypercalcaemia of malignancy and febrile neutropenia — without trying to manage them from this page.

  5. 5
    Take action

    Hold the infusion pending the interaction review and hand over clearly: "52-year-old woman, cycle 1 adjuvant chemotherapy for T2N1M0 breast cancer, anthracycline-containing. She takes phenytoin, a strong CYP inducer, and drinks grapefruit juice daily, an inhibitor — requesting pharmacy review before the first dose. Height and weight confirmed for BSA dosing. Baseline nutrition assessed, oral-care regimen started, and cumulative anthracycline dose documented." Then do the teaching, in her words. The lung question: if a spot appeared in her lung it would be metastatic breast cancer, treated as stage 4 breast cancer, not lung cancer, and pathologists can tell because the cells look like the breast primary rather than like lung tissue. The "why me" question: cancer is a genetic disease, but the changes usually come from errors as cells divide or environmental DNA damage, and the body’s clearance of damaged cells declines with age — most cancers are not inherited. The grandchildren question: external beam radiation will not make her radioactive, and she may safely be around other people, including pregnant women, babies and young children. Add the two instructions that come with radiation: the skin markings must stay because they position her identically every day, and the coloured lights are harmless. Three traps to avoid: giving her a memorised "nadir is 7 to 14 days" figure that no source supports, putting her on a neutropenic diet, and letting the word "palliative" be introduced for the first time at the point her treatment stops working.

  6. 6
    Evaluate

    Day 8 she reports mouth soreness — squarely inside the sourced five-to-fourteen-day window, and confirmation that the oral-care and nutrition plan started at the right time rather than late. Reassess intake, treat pain, and watch for the two consequences that matter: a breached mucosal barrier as a route to local or systemic infection, and a reduced or delayed next cycle, which "worsens prognosis." She is reminded that fever now is an emergency. Success looks like: the interaction resolved before dosing, mucositis identified early and intake maintained, no missed fever, the cumulative anthracycline dose recorded, and her three questions answered in words she can repeat to her family. Six months on, she has completed radiation with her markings intact, held her grandchildren throughout, and has palliative care involved for symptom control alongside ongoing treatment — because it "can begin at any point" and "can be given with or without curative care." Her stage is still recorded as it was at diagnosis, whatever happens next, because "the stage doesn’t change, even though the cancer might." And the survivorship record now names the agents she received, which is what a clinician five to seven years from now will need if a treatment-related leukaemia is ever a question.

Scenario — you’re the nurse

Work each question before revealing the answer. Rationales explain the wrong options too.

Oncology day unit · cycle 1, then day 8, then six months on

A 52-year-old woman whose screening mammogram found a mass. Biopsy confirms invasive carcinoma. She is starting adjuvant combination chemotherapy including an anthracycline, with external beam radiation planned after surgery. She has three grandchildren and has asked whether she will be safe around them.

Screening history — biennial mammography since age 40, under the 2024 USPSTF Grade B recommendation
Staging — reported as T2N1M0: a larger primary, cancer in nearby nodes, no distant metastasis
Regimen — combination chemotherapy, body-surface-area dosed, including an anthracycline
Home medicines — she takes phenytoin for a seizure disorder and drinks grapefruit juice each morning
Questions she has asked — "Will it become lung cancer if it spreads?" · "Why me, when nobody in my family has had this?" · "Will I be radioactive?"
Q1 Multiple choice
A patient with breast cancer is told a new lesion has been found in her liver. She asks the nurse whether she now has liver cancer as well. Which response is correct?
  1. A. Yes — a tumour in the liver is liver cancer, and it will be treated as a second primary cancer.
  2. B. No — it is metastatic breast cancer, treated as stage 4 breast cancer, because the cells keep the features of the original cancer.
  3. C. It cannot be determined without repeating the mammogram.
  4. D. It depends on whether the liver lesion is larger than the breast tumour.
Reveal answer & rationale
Answer: B
The naming rule is quoted directly: "metastatic cancer has the same name and the same type of cancer cells as the original, or primary, cancer," so breast cancer forming a tumour elsewhere "is metastatic breast cancer, not lung cancer," and it "is treated as stage 4 breast cancer" (B). Option A inverts the rule. The pathology is what settles it, not repeat screening (C) — metastatic cells "have features like that of the primary cancer and not like the cells in the place where the metastatic cancer is found," which "is how doctors can tell that it is cancer that has spread." Relative size (D) has no bearing; the T of the TNM string describes the size and extent of the primary, while the M simply records whether the cancer has metastasised.
Q2 Multiple choice
A patient starting external beam radiation therapy asks whether she should stay away from her infant grandson during the treatment course. Which response is supported?
  1. A. She should stay at least two metres away from children and pregnant women for the whole course.
  2. B. She should limit contact to fifteen minutes per visitor per day.
  3. C. External beam radiation will not make her radioactive, and she may safely be around other people, including pregnant women, babies and young children.
  4. D. She should wash off her skin markings before holding him.
Reveal answer & rationale
Answer: C
The reassurance is sourced verbatim: "external beam radiation therapy will not make you radioactive… you may safely be around other people, even pregnant women, babies, and young children" (C). Options A and B import time-and-distance rules that belong to a different situation and that no fetched source supplies for this one — for internal radiation the only sourced statement is that "the radiation source in your body will give off radiation for a while," with specific precautions coming from the radiation-safety plan for that patient. Option D reverses a real instruction: the skin dots "will be needed throughout your course of radiation therapy" so that she is positioned "in exactly the same position for every treatment."
Q3 Select all that apply
On day 8 of cycle 1 the patient reports several new findings. Which require follow-up rather than reassurance? Select all that apply.
  1. A. A temperature of 38.4 °C
  2. B. Mouth soreness that stops her finishing a drink
  3. C. New mid-back pain that woke her in the night
  4. D. Hair coming out on the pillow
  5. E. The small ink dots on her chest are still visible
Reveal answer & rationale
Answer: A, B, C
Three of the five are act-now findings and two are expected. The temperature (A) is the emergency: fever in a patient on chemotherapy is an emergency, because the neutrophil nadir after a cycle and the loss of the mucosal barrier from mucositis coincide — and this page deliberately does not supply a threshold, because the febrile-neutropenia pathway is owned by the leukemias and oncologic-emergencies pages. Mouth soreness limiting intake (B) is mucositis inside the sourced five-to-fourteen-day window, and it matters twice over: the lesions "weaken the mucosa barrier resulting in local or systemic infection," and "oral intake may be impaired due to pain, which in some cases may lead to the need for parenteral nutrition." New back pain (C) is one of the triggers for the oncologic-emergencies pathway — spinal cord compression is among the five emergencies this page names and does not teach, and new back pain in a patient with cancer is the cue to escalate rather than to medicate. Hair loss (D) is an expected class toxicity: chemotherapy acts on rapidly multiplying cells including hair follicles, and alopecia is named alongside myelosuppression and mucositis. The visible ink dots (E) are not a problem but a requirement — they "will be needed throughout your course of radiation therapy" so she is positioned "in exactly the same position for every treatment."
Q4 Put in order
Put the nurse’s actions before the first infusion in order:
  1. A. Confirm an accurate height and weight
  2. B. Escalate the phenytoin and grapefruit juice to pharmacy and the prescriber
  3. C. Assess nutritional status and start the oral-care plan
  4. D. Teach that fever after this cycle is an emergency
Reveal answer & rationale
Correct order: B → A → C → D
The interaction review (B) comes first because it can change today’s dose and because nothing downstream matters if the drug is wrong. "Drug-drug interactions are expected," cytochrome P450 metabolises many of these agents, and the source names phenytoin among strong inducers and grapefruit juice among inhibitors. Height and weight (A) come next because the dose is calculated from them — agents "are generally administered using body surface area dosing" — so an estimated weight is a dosing error waiting to happen. Nutrition and oral care (C) follow, and they are started now rather than when her mouth is already sore, because "the frequency of mucositis is higher in patients with poor nutritional status and inadequate oral care." The fever teaching (D) is last only in sequence, not in importance: it is the single most consequential thing she will take home, and it is taught once the immediate safety checks are done and she can absorb it.
Q5 Multiple choice
The patient asks whether agreeing to see the palliative care team means her treatment is being stopped. Which response is correct?
  1. A. Palliative care begins when curative treatment is no longer the goal, so it would mean stopping treatment.
  2. B. Palliative care can begin at any point during cancer treatment and can be given with or without curative care.
  3. C. Palliative care and hospice are the same service under two names.
  4. D. Palliative care is only available once a prognosis of less than six months has been certified.
Reveal answer & rationale
Answer: B
The distinction is one sourced sentence, and option A gets the halves the wrong way round. Palliative care "can begin at ANY POINT during cancer treatment" and "can be given WITH OR WITHOUT curative care" (B) — whereas hospice care "begins when curative treatment is no longer the goal of care and the sole focus is quality of life," which is what option A actually describes. Option C collapses two different services: palliative care runs alongside oncology treatment through a multidisciplinary team that "works together with the oncology care team," and the same tools are used both ways — "chemotherapy or radiation therapy to slow the growth of a tumor that is causing pain." Option D imports hospice’s eligibility rule — the recertified prognosis of less than 6 months, across two 90-day benefit periods then unlimited 60-day periods — into a service that has no such requirement. Coverage is not the barrier either: "private health insurance usually covers palliative care services," and Medicare Part B pays for some symptom-management services.

Common questions

What causes cancer fundamentals & treatment care?
Common causes and risk factors include older age — "the body normally eliminates cells with damaged dna before they turn cancerous. but the body’s ability to do so goes down as we age," and cancer-causing changes "accumulate slowly as a person ages", tobacco smoke — nci names "the chemicals in tobacco smoke" among the harmful environmental substances that damage dna, ultraviolet radiation — nci names "ultraviolet rays from the sun" alongside tobacco smoke as an environmental cause of dna damage, inherited mutations — one of the three sourced origins of a cancer-causing change, and the only one that runs in families, a known brca mutation, or a first-degree relative with one — a hereditary finding that changes how intensively a person is screened, not a gene class this page defines, and others.
What are the early signs of cancer fundamentals & treatment care?
Early findings include Nothing at all — the presentation screening exists to catch, Mouth soreness and ulceration in the first two weeks of treatment.
Does a benign tumour mean there is nothing to worry about?
No, and the source says so in the same breath as the definition. Benign describes behaviour: "benign tumors do not spread into, or invade, nearby tissues. When removed, benign tumors usually don’t grow back, whereas cancerous tumors sometimes do." Then immediately: "Benign tumors can sometimes be quite large, however. SOME CAN CAUSE SERIOUS SYMPTOMS OR BE LIFE THREATENING, SUCH AS BENIGN TUMORS IN THE BRAIN." A benign mass in a fixed space kills by pressure without ever invading anything. The mirror error is just as common — assuming a tumour means cancer. "Tumors can be cancerous or not cancerous," hyperplasia is a tissue change where "the cells and the way the tissue is organized still look normal," and carcinoma in situ carries the most confusing label in oncology: it is numbered Stage 0, and in the same sentence, "CIS is NOT cancer, but it may become cancer."
Why do chemotherapy side effects always seem to be the same four things?
Because they follow from one property of the drugs, and the source states it in a single sentence: "MOST CHEMOTHERAPY DRUGS SHOW ACTIVITY IN RAPIDLY MULTIPLYING CELLS, SO THEY TEND TO AFFECT RAPIDLY MULTIPLYING CELLS, eg, BONE MARROW, GI TRACT, AND HAIR FOLLICLES." Three fast-turnover tissues, three symptom clusters: marrow gives myelosuppression, gut lining gives nausea, vomiting, diarrhoea and mucositis, and hair follicles give alopecia — with sterility, infertility and infusion reactions named alongside them. Even mucositis has the same explanation at tissue level: "the BASAL EPITHELIAL LAYER of the oral mucosa has a RAPID CELLULAR TURNOVER, making the oral epithelium SUSCEPTIBLE to [treatment] injury." Once a student sees that the toxicity list is a list of fast-dividing tissues, they stop memorising it. The same logic explains why combinations are chosen "with different mechanisms of action and nonoverlapping toxicities."
What is the ANC threshold for febrile neutropenia?
The definition has two halves that must both be met, and the leukemias page owns it. Fever is "a single oral temperature greater than or equal to 101 F (38.3 C) or a temperature greater than or equal to 100.4 F (38 C) for at least an hour"; the neutropenia half used for febrile neutropenia is an ANC at or below 500, or one expected to fall to that level within 48 hours (the definition the leukemias page carries); and "In profound neutropenia, the ANC is less than 100 cells/microliter." Keep the severity ladder separate from the definition: an ANC below 500/µL is also where the ladder puts severe neutropenia, so the same number answers two different questions and is worth saying twice on purpose. What this page does NOT give you is the pathway — the risk stratification, the choice of empiric agent and the rule that intravenous antibiotics go in within an hour are owned by the leukemias and oncologic-emergencies pages, and they should be read there. And the rule that does not depend on any number: fever in a patient on chemotherapy is an emergency. And while you are there: do not order a neutropenic diet. The trial evidence against it is on the leukemias page. Standard food safety replaces it.
What is the difference between palliative care and hospice?
One sentence, quoted from the National Cancer Institute, does the whole job: "WHEREAS PALLIATIVE CARE CAN BEGIN AT ANY POINT DURING CANCER TREATMENT, HOSPICE CARE BEGINS WHEN CURATIVE TREATMENT IS NO LONGER THE GOAL OF CARE AND THE SOLE FOCUS IS QUALITY OF LIFE." Palliative care "can be given WITH OR WITHOUT curative care" and addresses "the person as a whole, not just their disease," through a multidisciplinary team that "works together with the oncology care team." It uses the same tools the disease is treated with — "chemotherapy or radiation therapy to slow the growth of a tumor that is causing pain," or surgery "to remove a mass that is pressing on certain nerves." Hospice eligibility, recertification and revocation follow Medicare rules, which change — ask the hospice team rather than relying on a memorised schedule.

Sources

Reviewed by Hae Suk Lee, RN

Educational summary for nursing students. Scenarios are fictional teaching cases. Always verify against current guidelines and your institution's protocols before acting in practice. Not medical advice.

Bookmark LearnDrugs.com?

Your saved pages are kept in this browser. Add LearnDrugs.com to your browser’s bookmarks to get back to them in one click.

Drag this link to your bookmarks bar: LearnDrugs.com

Or press Ctrl + D to bookmark the page you’re on.